Our vision
To develop a medication against skin atrophy.
Our objective
Trophea aims to develop the project up to and including clinical Phase II, i.e. proof of concept showing efficacy and safety of the newly developed combination product.
Trophea is addressing the medical need for an effective treatment of skin atrophy caused by long-term use of topical glucocorticoids. The project is based on an innovative combination of two well-known and studied substances that seem to offer positive synergistic efficacy on skin atrophy. Trophea’s product candidate is in preclinical phase.
To develop a medication against skin atrophy.
Trophea aims to develop the project up to and including clinical Phase II, i.e. proof of concept showing efficacy and safety of the newly developed combination product.